Species |
Human |
Protein Construction |
CD160 (Ile27-Ser159) Accession # O95971 |
hFc |
N-term |
C-term |
|
Purity |
> 95% as analyzed by SDS-PAGE |
Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
Biological Activity |
Immobilized CD160, hFc, Human at 1.0 μg/ml (100 μl/well) can bind HVEM-Fc, Human-Biotin with a liner range of 0.617-50.0 μg/ml when detected by SA-HRP. |
Expression System |
HEK 293 |
Apparent Molecular Weight |
~50 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Target Background |
CD160 is a glycosylphosphatidylinositol-anchored Ig domain protein that is expressed on almost all intestinal intraepithelial lymphocytes (IELs), γδ T (gamma delta T) cells, NK (natural killer) cells, and a minor subset of CD4+ and CD8+ T cells. In terms of function, work has centered on the role of CD160 in enhancing NK or CD8 T cell activation. Such effects have been attributed to the ability of CD160 to bind classical and nonclassical MHC class I molecules, although with apparent low affinity, requiring clustering of MHC class I molecules or overexpression of CD160 or MHC class I for detection of the interaction. |
Synonyms |
BY55; NK1; NK28 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.